Federal Circuit Affirms Invalidity Of Toprol Patents
An appellate court on Monday upheld a ruling finding AstraZeneca PLC's patents covering its blockbuster heart drug Toprol-XL invalid due to obviousness, but overturned a lower court's ruling of inequitable conduct....To view the full article, register now.
Already a subscriber? Click here to view full article